The U.S. Food and Drug Administration has granted breakthrough therapy designation to Sanofi’s (SNY) venglustat, a novel, ...

Obesity is widely known for increasing the risk of diabetes and cardiovascular disease, but its damaging effects on the ...

Obesity is widely known for increasing the risk of diabetes and cardiovascular disease, but its damaging effects on the skeleton are often overlooked ...

Researchers show that pharmacological activation of hypoxia signaling improves metabolism, limits fat accumulation, and ...

In the open-label FIBROMET trial, metformin treatment was associated with reductions in bone marrow fibrosis and downregulation of key oncogenic signaling pathways in patients wit ...

Key Takeaways An already approved drug can protect cancer patients from bleeding due to chemoPatients taking romiplostim had ...

EpiTracing" has proved capable of detecting and tracing diseases from as little as 50 μl of human plasma, roughly a drop of ...

Sanofi’s venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy ...

Pharmacosmos initiates phase III clinical trial of trilaciclib in limited-stage small cell lung cancer MORRISTOWN, NJ, ...

A “VERY talented” young student, 20, died after he contracted sepsis from “inadequate hospital hygiene”. Joshua ...

Sanofi's venglustat earns Breakthrough Therapy designation in the US for type 3 Gaucher disease Paris, March 18, 2026. The US Food and Drug Administration (FDA) has granted Breakthrough Therapy design ...

AN2 Therapeutics, Inc. (Nasdaq: ANTX), a clinical stage biopharmaceutical company focused on the discovery and development of novel small molecule therapeutics derived from its boron chemistry ...